Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. [electronic resource]
Producer: 20171108Description: 16-23 p. digitalISSN:- 1872-8332
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Biomarkers, Tumor -- metabolism
- CD56 Antigen -- immunology
- DNA-Binding Proteins -- immunology
- Female
- Humans
- Indazoles
- Leukocyte Common Antigens -- immunology
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplastic Cells, Circulating -- drug effects
- Non-Randomized Controlled Trials as Topic
- Pyrimidines -- administration & dosage
- Small Cell Lung Carcinoma -- drug therapy
- Sulfonamides -- administration & dosage
- Transcription Factors
- Vascular Endothelial Growth Factor Receptor-2 -- immunology
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.